key: cord-0778121-mvw5hr33 authors: Kanji, J. N.; Proctor, D.; Stokes, W.; Berenger, B. M.; Silvius, J.; Tipples, G.; Joffe, A. M.; Venner, A. A. title: Multi-centre post-implementation evaluation of SARS-CoV-2 antigen-based point of care tests used for asymptomatic screening of continuing care healthcare workers date: 2021-06-25 journal: nan DOI: 10.1101/2021.06.22.21259345 sha: 7df550d6b9ab4d01b74457d66e0b36c4dd1c81c7 doc_id: 778121 cord_uid: mvw5hr33 Frequent screening of SARS-CoV-2 among asymptomatic populations using antigen-based point of care tests (APOCT) is occurring globally with limited clinical performance data. The positive predictive value (PPV) of two APOCT used in the asymptomatic screening of SARS-CoV-2 among healthcare workers (HCW) at continuing care (CC) sites across Alberta, Canada was evaluated. Between February 22 and May 2, 2021, CC sites implemented SARS-CoV-2 voluntary screening of their asymptomatic HCW. Onsite testing with Abbott Panbio or BD Veritor occurred on a weekly or twice weekly basis. Positive APOCT were confirmed with a real-time reverse-transcriptase polymerase chain reaction (rRT-PCR) reference method. A total of 71,847 APOCT (17,689 Veritor and 54,158 Panbio) were performed among 369 CC sites. Eighty-seven (0.12%) APOCT were positive, of which 39 (0.05%) confirmed as true positives using rRT-PCR. Use of the Veritor and Panbio resulted in a 76.6% and 30.0% false positive detection, respectively (p<0.001). This corresponded to a 23.4% and 70.0% PPV for the Veritor and Panbio, respectively. Frequent screening of SARS-CoV-2 among asymptomatic HCW in CC, using APOCT, resulted in a very low detection rate and a high detection of false positives. Careful assessment between the risks vs benefits of APOCT programs in this population needs to be thoroughly considered before implementation. implementation of APOCT programs [1] . 89 90 Rapid and wide-scale deployment of APOCT has been promoted despite limited data 91 regarding the analytical and clinical performance of these devices in the various settings in 92 which they have been used. POCT programs that include APOCT have been criticised for the 93 poor sensitivity of these tests compared to PCR tests, particularly in asymptomatic 94 individuals [2] . However, there has been intense interest in testing asymptomatic individuals 95 from a public health perspective, as some estimate that 30 to 40 percent of infectious 96 individuals are asymptomatic. Rapid identification and isolation of these individuals is 97 viewed as highly effective in breaking chains of transmission [1, [3] [4] [5] . However, there is 98 concern that APOCT may demonstrate poor specificity when used for the surveillance of 99 asymptomatic individuals, with reports citing up to 60% false positive rates [6, 7] . 100 101 Routine serial testing of asymptomatic staff in continuing care facilities using APOCT has 102 been implemented as a purportedly important public health measure for early case 103 identification, and prevention of SARS-CoV-2 outbreaks among vulnerable residents [1, [3] [4] [5] . Setting 116 Asymptomatic SARS-CoV-2 testing of HCWs in continuing care facilities province-wide 117 was implemented as POCT as part of the provincial pandemic response in the province of 118 Adjunctive eye protection (face shield or goggles) was advised during all episodes of patient 129 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. accounted for (0.05%). Therefore, when considering the true positivity rate, the yield of 225 asymptomatic screening programs is poor. 226 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The principal limitation of this study is that only positive APOCT tests were confirmed by 262 rRT-PCR, and thus no other test parameters other than a PPV could be calculated. The data 263 however, still confirms in a large asymptomatic HCW population, that APOCT has a low 264 PPV. The major strengths of this study lie in the large number of tests performed, 265 participating sites, and inclusion of two different APOCT platforms. 266 The utility of screening asymptomatic individuals with COVID-19 APOCT is best 268 determined by weighing the costs and benefits specific to each setting. With widespread 269 vaccination increasing and disease prevalence falling, fewer positive test results are likely to 270 be found among asymptomatic persons in the coming months (with a large proportion of 271 them being false-positives), leading such endeavors to be quite costly from a materials and 272 human resources perspectives for most health care systems. Therefore, it is important to 273 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 25, 2021. ; https://doi.org/10.1101/2021.06.22.21259345 doi: medRxiv preprint reconsider the value and effectiveness of asymptomatic APOCT COVID-19 programs over 274 the long term, especially in the context of increasing population immunity. 275 276 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. None of the authors have any conflicts of interests with respect to this manuscript to declare. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The datasets used and/or analysed during the current study are available from the 317 corresponding author on reasonable request. 318 319 320 321 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 448 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 25, 2021. ; https://doi.org/10.1101/2021.06.22.21259345 doi: medRxiv preprint Priority strategies to optimize testing and screening for COVID-324 19 in Canada Rapid, point-of-care antigen and 331 molecular-based tests for diagnosis of SARS-CoV-2 infection Put to the test: use of rapid testing 334 technologies for covid-19 Rapid antigen tests for SARS-CoV-2 Nevada Halts Use of Rapid Coronavirus Tests in Nursing Homes, Citing 341 Inaccuracies Covid-19: Tests on students are highly inaccurate, early findings show Government of Alberta, Population statistics Performance of an Antigen-Based Test for Asymptomatic and 374 Symptomatic SARS-CoV-2 Testing at Two University Campuses -Wisconsin Nasopharyngeal Panbio COVID-19 Antigen Performed at Point-of-379 Care Has a High Sensitivity in Symptomatic and Asymptomatic Patients With Higher Risk 380 for Transmission and Older Age COVID-19 screening of asymptomatic patients admitted through emergency 383 departments in Alberta: a prospective quality-improvement study Validation testing to determine the sensitivity of lateral flow 388 testing for asymptomatic SARS-CoV-2 detection in low prevalence settings: Testing 389 frequency and public health messaging is key SARS-CoV-2 in healthcare workers during the pandemic: a Spanish experience CoV-2 nucleic acid screening in nearly ten million residents of Wuhan CoV-2 Screen Testing of Ontario Long-Term Care Staff After COVID-19 Vaccination CoV-2 Rapid Antigen Testing in the Emergency Ward of a Swiss University Hospital: The 405 INCREASE Study, Microorganisms Evaluation of a rapid antigen 407 test (Panbio™ COVID-19 Ag rapid test device) for SARS-CoV-2 detection in asymptomatic 408 close contacts of COVID-19 patients Performance characteristics of five antigen-detecting rapid diagnostic test (Ag-RDT) for SARS-CoV-2 asymptomatic infection: a head-to-head benchmark comparison False-positive COVID-19 results: 416 hidden problems and costs The impact of false positive COVID-418 19 results in an area of low prevalence